Literature DB >> 27898215

Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial.

Momen M Wahidi1, Chakravarthy Reddy2, Lonny Yarmus3, David Feller-Kopman3, Ali Musani4, R Wesley Shepherd5, Hans Lee3, Rabih Bechara6, Carla Lamb7, Scott Shofer1, Kamran Mahmood1, Gaetane Michaud8, Jonathan Puchalski9, Samaan Rafeq10, Stephen M Cattaneo11, John Mullon12, Steven Leh13, Martin Mayse14, Samantha M Thomas15, Bercedis Peterson15, Richard W Light16.   

Abstract

RATIONALE: Patients with malignant pleural effusions have significant dyspnea and shortened life expectancy. Indwelling pleural catheters allow patients to drain pleural fluid at home and can lead to autopleurodesis. The optimal drainage frequency to achieve autopleurodesis and freedom from catheter has not been determined.
OBJECTIVES: To determine whether an aggressive daily drainage strategy is superior to the current standard every other day drainage of pleural fluid in achieving autopleurodesis.
METHODS: Patients were randomized to either an aggressive drainage (daily drainage; n = 73) or standard drainage (every other day drainage; n = 76) of pleural fluid via a tunneled pleural catheter.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the incidence of autopleurodesis following the placement of the indwelling pleural catheters. The rate of autopleurodesis, defined as complete or partial response based on symptomatic and radiographic changes, was greater in the aggressive drainage arm than the standard drainage arm (47% vs. 24%, respectively; P = 0.003). Median time to autopleurodesis was shorter in the aggressive arm (54 d; 95% confidence interval, 34-83) as compared with the standard arm (90 d; 95% confidence interval, 70 to nonestimable). Rate of adverse events, quality of life, and patient satisfaction were not significantly different between the two arms.
CONCLUSIONS: Among patients with malignant pleural effusion, daily drainage of pleural fluid via an indwelling pleural catheter led to a higher rate of autopleurodesis and faster time to liberty from catheter. Clinical trial registered with www.clinicaltrials.gov (NCT 00978939).

Entities:  

Keywords:  indwelling pleural catheter; malignant pleural effusions; pleurodesis

Mesh:

Year:  2017        PMID: 27898215     DOI: 10.1164/rccm.201607-1404OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

1.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  Tunneled pleural catheter use for pleural palliation does not increase infection rate in patients with treatment-related immunosuppression.

Authors:  Candice L Wilshire; Christopher R Gilbert; Brian E Louie; Ralph W Aye; Alexander S Farivar; Eric Vallières; Jed A Gorden
Journal:  Support Care Cancer       Date:  2017-11-29       Impact factor: 3.603

3.  Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.

Authors:  Christopher Kniese; Khalil Diab; Marwan Ghabril; Gabriel Bosslet
Journal:  Chest       Date:  2018-07-07       Impact factor: 9.410

4.  Open window thoracostomy as an alternative approach to secondarily infected malignant pleural effusion and failure of intrapleural catheter drainage: a case report.

Authors:  Anthony M Villano; Raul Caso; M Blair Marshall
Journal:  AME Case Rep       Date:  2018-04-13

5.  Pleural Disease Management: Manometry-guided Thoracentesis, Optimal Drainage Regimen of Indwelling Pleural Catheters, and Talc Poudrage versus Slurry for Malignant Pleural Effusion.

Authors:  Andrea Mytinger; Trevor Taylor; Evgeni Gershman; Samira Shojaee
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 21.405

6.  Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening.

Authors:  Andrea Mazzocchi; Mahesh Devarasetty; Samuel Herberg; William J Petty; Frank Marini; Lance Miller; Gregory Kucera; David K Dukes; Jimmy Ruiz; Aleksander Skardal; Shay Soker
Journal:  ACS Biomater Sci Eng       Date:  2019-03-08

Review 7.  Contemporary approach to the patient with malignant pleural effusion complicating lung cancer.

Authors:  Oleg Epelbaum; Najib M Rahman
Journal:  Ann Transl Med       Date:  2019-08

8.  Indwelling Pleural Catheters for Patients with Hematologic Malignancies. A 14-Year, Single-Center Experience.

Authors:  Saadia A Faiz; Priyanka Pathania; Juhee Song; Liang Li; Diwakar D Balachandran; David E Ost; Rodolfo C Morice; Vickie R Shannon; Lara Bashoura; Georgie A Eapen; Carlos A Jimenez
Journal:  Ann Am Thorac Soc       Date:  2017-06

Review 9.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 10.  Management of Malignant Lung Entrapment, the Oncothorax.

Authors:  Roman Petrov; Charles Bakhos; Abbas E Abbas
Journal:  Thorac Surg Clin       Date:  2018-02       Impact factor: 1.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.